Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX)’s Suzetrigine: ‘I Don’t See A Lot Of Upside Because That Was The Drug Of The Future For Vertex’
We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...
Vertex Pharmaceuticals’ JOURNA VX: Navigating Market Challenges Despite Promising Financial Outlook
Needham analyst Joseph Stringer has maintained their neutral stance on VRTX stock, giving a Hold rating today.Invest with Confidence: Follow ...
The Washington Post18d
Billed as nonaddictive, new pain pill could soon win FDA approval
If successful, the drug developed by Vertex Pharmaceuticals would offer a ... at the Center for Pain Relief at the University of Washington Medical Center-Roosevelt. “It’s a fantasy to think ...
NBC News on MSN13d
'Will it really work?': Young sickle cell patient among the first to start new gene therapy
Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...
The Tokenist2h
Vertex Pharmaceuticals Stock Soars as Non-Opiod Pain Treatment Gets FDA Nod
Vertex Pharmaceuticals' newly FDA-approved non-opioid analgesic, Journavx, offers a groundbreaking alternative for managing ...
Vertex Pharmaceuticals price target raised to $435 from $418 at Barclays
Barclays analyst Gena Wang raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $435 from $418 and keeps an Equal Weight rating ...
Morningstar1d
American Funds Washington Mutual R6
Nondividend payers, such as the fund's positions in Vertex Pharmaceuticals and Royal Caribbean Group, are capped at 5%. While the strategy has excluded alcohol or tobacco companies previously ...
Seeking Alpha3d
VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...